Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NSD2 | O96028 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | HSD11B1 | P28845 | 3/20 | 0.47 |
| ▸ | EDNRA | P25101 | 2/20 | 0.46 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.46 |
| ▸ | PGR | P06401 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2803354 | 0.85 | NSD2 (0.58) | NSD2ALDH1A1KDM4EMEN1NPC1 | |
| SCHEMBL15560488 | 0.85 | NSD2 (0.51) | NSD2GAATSHRPGRKDM4E | |
| SCHEMBL22648418 | 0.82 | PARG (0.50) | ALDH1A1GAATSHRHSD17B10L3MBTL1 | |
| SCHEMBL8908300 | 0.82 | NSD2 (0.49) | NSD2ALDH1A1HSD11B1KDM4EMEN1 | |
| SCHEMBL14676017 | 0.80 | SLC1A3 (0.49) | ALDH1A1GAATSHRHSD17B10L3MBTL1 | |
| SCHEMBL12932761 | 0.80 | LMNA (0.50) | NSD2ALDH1A1GAATSHRMCL1 | |
| SCHEMBL2371935 | 0.79 | GAA (0.58) | ALDH1A1GAATSHRHSD17B10L3MBTL1 | |
| SCHEMBL6928314 | 0.79 | ALDH1A1 (0.56) | ALDH1A1GAATSHRHSD17B10L3MBTL1 | |
| SCHEMBL21690364 | 0.78 | DUT (0.56) | ALDH1A1GAATSHRHSD17B10L3MBTL1 | |
| SCHEMBL23345388 | 0.78 | NSD2 (0.51) | NSD2ALDH1A1KDM4EMEN1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220194945-A1 | Imidazolopyridine Compounds For IRE1 Inhibition | Optikira, LLC | 2022-06-23 | — | — | US | disclosed |
| US-20220153734-A1 | Pyrazolopyridine Compounds For IRE1 Inhibition | Optikira, LLC | 2022-05-19 | — | — | US | disclosed |
| US-20200354367-A1 | COMPOUNDS AND COMPOSITIONS FOR IRE1 INHIBITION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2020-11-12 | — | — | US | disclosed |
| US-20110015185-A1 | Benzofuran Compounds | BIOVITRUM AB (SE) | 2011-01-20 | — | — | US | disclosed |
| US-7820675-B2 | Benzofuran compounds | BIOVITRUM AB (SE) | 2010-10-26 | — | — | US | disclosed |
| US-7820675-B2 | Benzofuran compounds | BIOVITRUM AB (SE) | 2010-10-26 | — | — | US | disclosed |
| US-7674810-B2 | 1,1-dioxo-1H-1Λ6-benzo[d]isothiazol-3-yl)-4-hydroxy-1,5-dihydro-pyrrol-2-one inhibitors of HCV polymerase | ROCHE PALO ALTO LLC (US) | 2010-03-09 | — | — | US | disclosed |
| CN-101189230-A | Heterocyclic antiviral compounds | ROCHE PALO ALTO LLC (CH) | 2008-05-28 | — | — | CN | disclosed |
| EP-1879885-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | F. Hoffmann-Roche AG (CH) | 2008-01-23 | — | — | EP | disclosed |
| US-20060252785-A1 | Heterocyclic antiviral compounds | ROCHE PALO ALTO LLC | 2006-11-09 | — | — | US | disclosed |
| US-4867781-A | PRE- AND POSTEMERGENCE HERBICIDES; NONPHYTOTOXIC | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1989-09-19 | — | — | US | disclosed |
| US-4842639-A | HERBICIDES | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1989-06-27 | — | — | US | disclosed |
| US-4802911-A | HERBICIDES, PLANT GROWTH REGULATORS | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1989-02-07 | — | — | US | disclosed |
| EP-0107979-B1 | NOVEL PHENYL-SUBSTITUTED SULFONAMIDES | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1988-10-12 | — | — | EP | disclosed |
| US-4741761-A | HERBICIDES | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1988-05-03 | — | — | US | disclosed |
| US-4643761-A | Herbicidal sulfonamides | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1987-02-17 | — | — | US | disclosed |
| US-4620870-A | HERBICIDES | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1986-11-04 | — | — | US | disclosed |
| US-4586950-A | HERBICIDES | E. I. DU PONT DE NEMOURS & COMPANY (US) | 1986-05-06 | — | — | US | disclosed |
| EP-0166516-A2 | Novel phenyl-subsituted sulfonamides | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1986-01-02 | — | — | EP | disclosed |
| EP-0107979-A1 | Novel phenyl-substituted sulfonamides | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1984-05-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200354367-A1 | COMPOUNDS AND COMPOSITIONS FOR IRE1 INHIBITION | XBP1, RNASE1, ERN1 | NSD2 4236/4885ALDH1A1 2682/4885GAA 548/4885 |
| US-20060252785-A1 | Heterocyclic antiviral compounds | EIF2AK2, HAVCR2, POLR2E | NSD2 161/4885ALDH1A1 431/4885GAA 925/4885 |
| US-20220194945-A1 | Imidazolopyridine Compounds For IRE1 Inhibition | XBP1, ERN2, ERN1 | NSD2 3602/4885ALDH1A1 2541/4885GAA 1410/4885 |
| US-20220153734-A1 | Pyrazolopyridine Compounds For IRE1 Inhibition | XBP1, ERN1, ERN2 | NSD2 3784/4885ALDH1A1 2438/4885GAA 1578/4885 |
| US-20110015185-A1 | Benzofuran Compounds | HTR6, HTR1F, HTR1A | NSD2 2207/4885ALDH1A1 353/4885GAA 2323/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.